CBCT evaluation of inter- and intra-fraction motions during prostate stereotactic body radiotherapy: a technical note

Omar Jmour, Marouan Benna, Pierre Champagnol, Majed Ben Mrad, Anis Hamrouni, Layal Obeid, Chaimaa Lahmamssi, Amal Bousarsar, Nicolas Vial, Armel Rehailia-Blanchard, Sandrine Sotton, Meiling Lan, Julien Langrand-Escure, Alexis Vallard and Nicolas Magné*

Abstract

Background: In most clinical trials, gold fiducial markers are implanted in the prostate to tune the table position before each radiation beam. Yet, it is unclear if a cone-beam computed tomography (CBCT) should be performed before each beam to monitor a possible variation of the organs at risk (OARs) fullness, especially in case of recto-prostatic spacer implantation. The present study aimed at assessing the inter- and intra-fraction movements of prostate, bladder and rectum in patients implanted with a hyaluronic acid spacer and undergoing prostate stereotactic body radiotherapy (SBRT).

Methods: Data about consecutive patients undergoing prostate SBRT were prospectively collected between 2015 and 2019. Inter-and intra-fraction prostate displacements and volume variation of organs at risk (OARs) were assessed with CBCTs.

Results: Eight patients were included. They underwent prostate SBRT (37.5Gy, 5 fractions of 7.5Gy) guided by prostate gold fiducial markers. Inter-fraction variation of the bladder volume was insignificant. Intra-fraction mean increase of the bladder volume was modest (29 cc) but significant (p < 0.001). Both inter- and intra-fraction variations of the rectum volume were insignificant but for one patient. He had no rectal toxicity. The magnitude of table displacement necessary to match the prostate gold fiducial marker frequently exceeded the CTV/PTV margins (0.4 cm) before the first (35%) and the second arc (15%). Inter- and intra-fraction bladder and rectum volume variations did not correlate with prostate displacement.

Conclusion: Major prostate position variations were reported. In-room kV fiducial imaging before each arc seems mandatory. Intra-fraction imaging of the OARs appears unnecessary. We suggest that only one CBCT is needed before the first arc.

Trial registration: NCT02361515, February 11th, 2015.

Keywords: Prostate cancer, Radiotherapy, Stereotactic body radiotherapy, Cone beam CT, motion, Bladder, Rectum, Organs at risk

* Correspondence: nicolas.magne@icloire.fr
Department of radiation oncology, Lucien Neuwirth Cancer Institute, 108 Bis, Avenue Albert Raimond, 42270 Saint Priest en Jarez, France

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Recent phase 2 and 3 trials [1, 2] tend to show that ultra-hypofractionation (≥ 5 Gy per fraction) is the next step in the evolution of prostate cancer external beam radiotherapy [1, 2].

However, such high doses per fraction require a specific management of the inter- and intra-fraction movements of the target. In clinical trials, gold fiducial markers were implanted in the prostate to tune the table position before each radiation beam. Yet, it is unclear if a cone-beam computed tomography (CBCT) should be performed before each beam to monitor a possible variation of the organs at risk (OARs) fullness [3–5], especially when performed with hyaluronic acid spacer. The present technical note was designed to assess this question.

Methods and materials
Data about consecutive patients undergoing a curative prostate SBRT at the Lucien Neuwirth cancer center (France) were prospectively collected between 2015 and 2019.

Procedure
All patients had gold fiducial markers implanted in the prostate. A hyaluronic acid spacer was placed between the anterior rectal wall and the posterior face of the prostate. The CTV was defined as the prostate only on the CT images coupled with a T2w-MRI. The CTV–PTV margin was 0.4 cm in every direction. The rectum was delineated 2 cm above and under the PTV. The bladder was delineated entirely. Dose constraints were as follows. For the rectum: V37.5 Gy < 3 cc, V25Gy < 10 cc, V39.5 Gy < 1 cc. For the bladder: V39.5 Gy < 1 cc. For the “bladder-PTV”: V30Gy < 10 cc. Patients were treated with the RapidArc® technology based on 2 consecutive arcs and received 37.5 Gy in 5 fractions (beam energy: 6 MV) with at least 48 h between each fraction. Patients were treated on a Varian Truebeam (Varian, California, USA) and immobilized with a knee-immobilization device on a robotic 6-degree couch. They were asked to empty their bowel and bladder 60 min before each radiation course and then, to drink 350–500 cc. Before each arc, a CBCT was performed and a radiation oncologist decided which table displacements should be achieved to match the fiducial markers. Prostate and OARs were then contoured on the 2 CBCTs by one operator (2nd author, the same operator who contoured the planning CT).

Statistical analysis
Pearson’s correlation and Student tests were performed to compare prostate motion (i.e. table displacements) distributions. The paired student t-test was used to compare variations of OARs volume. The Fisher exact test was used to assess if toxicity and OARs fullness were linked. Significance was defined as $p < 0.05$.

Results
Patients and treatment characteristics
Eight patients were included. The mean duration of a fraction was 28 min (range: 13–62 min). No patient experienced biochemical or clinical failure during the 33-month median follow-up (range: 17–37). Two patients had acute grade 2 urinary toxicity (retention requiring a urinary catheter). There was no grade 2 digestive toxicity or acute grade ≥ 2 toxicity. Two patients experienced late grade 2 urinary toxicity (dysuria, urinary incontinence), one experienced late grade 3 urinary toxicity (incontinence) and one experienced late grade 2 digestive toxicity (rectal bleeding). There was no late grade > 3 toxicity.

Fiducial marker guided prostate radiotherapy

a. Inter-fraction assessment (Table 1)

The mean table displacement before the first arc was 0.06 cm in the antero-posterior direction (standard deviation (SD) = 0.35 cm, range: −0.89 cm to +0.88 cm), −0.04 cm in the antero-posterior direction (SD = 0.23 cm, range: −0.60 cm to +0.45 cm), and 0.00 cm in the left-right direction (SD = 0.27 cm, range: −1.96 cm to +0.51 cm).

b. Intra-fraction assessment (Table 1)

The mean table displacement before the second arc was −0.03 cm in the antero-posterior direction (SD = 0.34 cm, range: −1.80 cm to +1.64 cm), −0.07 cm in the supero-inferior direction (SD = 0.13 cm, range: −0.37 cm to +0.28 cm) and 0.04 cm in the left-right direction (SD = 0.23 cm, range: −0.40 cm to +1.79 cm).

Variation of OARs volume

1. Bladder

1.a. Inter-fraction assessment (Fig. 1).

The mean bladder volume on the planning CT-scan was 368 cc (range: 161–607 cc). Three patients had a mean bladder volume during SBRT (calculated on the CBCT performed before each of the five fractions) inferior to the bladder volume on the planning CT-scan (range: −10% to −29%).

When the whole set of patients was taken into account, there was no statistically significant inter-fraction variation of the mean bladder volume ($p = 0.12$). There was no correlation between bladder fullness and the
inter-fraction prostate movement (i.e. table displacement performed before the first arc) -whatever the considered direction (antero-posterior: \( r^2 = 0.31 \); supero-inferior: \( r^2 = 0.16 \); left-right: \( r^2 = -0.38 \)).

1.b. Intra-fraction assessment.

The mean bladder volume significantly increased between the first and the second arc (mean increase: 29 cc \( p < 0.001 \), Fig. 1). For four patients, the volume increased by 20%, at least once. Two patients experienced urinary leakage at least once and a decrease of bladder volume on the second CBCT (Fig. 2). There was no correlation between bladder fullness (assessed before the second arc) and the intra-fraction prostate movement (i.e. table displacement performed before the second arc) -whatever the considered direction (antero-posterior: \( r^2 = -0.02 \); supero-inferior: \( r^2 = -0.22 \); left-right: \( r^2 = -0.24 \)).

## Table 1

|                      | CBCT performed before the first arc | CBCT performed before the second arc |
|----------------------|------------------------------------|-------------------------------------|
|                      | Antero-posterior  | Supero-inferior  | Left-Right  | Antero-posterior  | Supero-inferior  | Left-Right  |
| Minimum value (cm)   | −0.89              | −0.60              | −1.96       | −1.80              | −0.37              | −0.40       |
| Maximum value (cm)   | + 0.88             | + 0.45             | + 0.51      | + 1.64             | + 0.28             | + 1.79      |
| Mean values± Standard deviation (cm) | 0.06 ± 0.35 | −0.04 ± 0.26 | 0.00 ± 0.27 | −0.03 ± 0.34 | −0.07 ± 0.13 | 0.04 ± 0.23 |
| Interval including 95.4% of values (cm) | Lower boundary: −0.63 | −0.56 | −0.55 | −0.70 | −0.32 | −0.42 |
|                      | Upper boundary      | + 0.76             | + 0.49      | + 0.55             | + 0.65             | + 0.19      | + 0.51      |
| Proportion of table displacement exceeding the CTV/PTV margin (0.4 cm), % | 35% | 30% | 17.5% | 12.5% | 5% | 15% |

2. **Rectum.**

1.a. Inter-fraction assessment (Fig. 3).

The mean rectum volume on the planning-CT was 66 cc (range:38–108.5 cc). The mean rectum volume assessed before the first arc did not significantly vary compared to the mean volume assessed on the planning-CT scan \( p = 0.40 \). There was no significant variation of inter-fraction rectal volume. There was no correlation between rectum fullness and the inter-fraction prostate movement whatever the considered direction (antero-posterior: \( r^2 = 0.10 \); supero-inferior: \( r^2 = 0.006 \); left-right: \( r^2 = 0.07 \)).

1.b. Intra-fraction assessment.

There was no significant variation of the mean rectum volume on the CBCT performed before the second arc.

![Fig. 1](image-url) Evolution of the mean bladder volume before and during SBRT fraction, compared to the bladder on planning CT-scan. The bladder volume assessed on the planning CT-scan divided the bladder volume assessed on the CBCT performed before the first (blue line) and the second arc (orange line) (1 = volumes were equal)
**Fig. 2** Individual data about the evolution of the bladder volume assessed during SBRT fraction, compared to the bladder assessed before SBRT fraction. The bladder volume assessed on the CBCT performed before the first arc divided the bladder volume assessed on the CBCT performed before the second arc (1 = volumes were equal). Abbreviation: P: Patient

**Fig. 3** Evolution of the mean rectum volume assessed before and during SBRT fraction, compared to the rectum on planning CT-scan. The rectum volume assessed on the planning CT-scan divided the rectum volume assessed on the CBCT performed before the first (blue line) and the second arc (orange line) (1 = volumes were equal)
when it was compared to the rectum on the CBCT performed before the first arc ($p = 0.76$, Fig. 3). For four patients, the variation reached 20% of the volume assessed on the first CBCT at least once. For one patient, the rectal volume variation exceeded 200% twice (Fig. 4). Intrafraction variation of rectum fullness and intra-fraction prostate movement did not correlate -whatever the considered direction (antero-posterior: $r^2 = 0.07$; supero-inferior: $r^2 = 0.21$; left-right: $r^2 = 0.40$).

Toxicity
Severe (grade ≥ 2) acute or late toxicity correlated neither with prostate movement nor with inter- or intra-fraction fullness of bladder or rectum. Two patients out of three who had suboptimal filled bladder (mean volume on CBCT inferior to the one on planning-CT) had severe late urinary toxicities. One of the five patients who had optimal filled bladder had severe late urinary toxicities.

Discussion
The present study reports on the intra- and inter-fraction movements of the target and the OARs during a prostate SBRT with hyaluronic acid spacer. Results are preliminary since they were assessed only through a monocentric experience in 8 patients. A huge amount of paper has been published on this topic for patients who had no hyaluronic acid spacer. Their results will not be discussed. Only three studies previously analyzed the inter- and intra-fractional motion with recto-prostatic spacers. Picardi et al. assessed the overall mean inter-fractional prostate displacements [6]. Displacements > 5 mm were found in 0.8, 12.3, and 6.5% CBCT acquisitions in the left-right, antero-posterior, and supero-inferior directions, respectively versus 10, 0 and 17% in our series. Intrafraction prostate motion was assessed by Juneja et al [7]. 5% of the fractions had mean motion more than 3 mm, even for the hypofractionated courses (mean motion: 0.5–2.7 mm for courses > 3 min). In our series, the intra-fraction prostate movement exceeded 3 mm in at least one axe for 32.5% of CBCTs. Hedrick et al. used the same methodology [8]. Maximal values of intra-fraction prostate motion were below 8 mm and only 2.5% exceeded 5 mm. In our series, the intra-fraction prostate movement exceeded 5 mm in at least one direction in 10%. In conclusion, the inter-and intra-fractions displacement assessed in the present study seems to be slightly superior to the ones reported in literature. However, fraction duration were longer in the present cohort. In our series, the proportion of table displacement exceeding the PTV margin (0.4 cm) only partially decreased after the second CBCT. That confirms that prostate movements during long fraction are significant. A fiducial imaging before each arc is mandatory. However, the magnitude of table displacement with extreme values exceeding 1.6 cm after the second CBCT should question the knee-immobilization device that was used. A vacuum-formable mattress could probably significantly avoid intra-fraction patient movements.

Regarding the bladder, there was no significant inter-fraction fullness variation. Urinary toxicities were not correlated with the inter- or intra-fraction variation of
the bladder volume. However, 2 out of the 3 patients who had suboptimal bladder fullness experienced severe late toxicity. This should probably call for a systematic CBCT assessment before each fraction to check the bladder is at least as full as it was on the planning-CT scan. No significant data was brought by the second CBCT (performed before the second arc). Regarding the rectum, there was no significant inter-fraction fullness variation. There was no major intra-fraction volume variation but for one patient who experienced no toxicity. This was expected since all patients had a hyaluronic acid spacer that prevented the rectal wall to move anteriorly [9] (Fig. 5). Therefore, thanks to rectal spacer, monitoring the variation of the rectal volume during SBRT fraction turns unnecessary. No significant data was given by the CBCT performed before the second arc. Thus, intra-fraction imaging of the OARs appears unnecessary.

Conclusion

Fiducial imaging (kV/kV) before each arc seems mandatory whereas intra-fraction imaging of the OARs appears unnecessary. We suggest that only one CBCT is needed before the first arc.

Abbreviations

CBCT: Cone-beam computed tomography; OAR: Organs at risk; kV: KiloVolt; SBRT: Stereotactic body radiotherapy; CTV: Clinical target volume; PTV: Planning target volume

Acknowledgements

None.

Authors’ contributions

MB performed the contouring of all CBCT and was a major contributor in writing the manuscript. OJ, AV, MBM, AH, JLE, SS, NM analyzed and interpreted the patient data regarding the intra/inter-fractional motions. They were major contributors in writing the manuscript. PC and LO performed all the statistics and were major contributors in writing the manuscript. CL, AB, NV, ARB, ML collected acute and late toxicities and were major contributors in writing the manuscript. All authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The institutional review board approved the study which was conducted in accordance with the Helsinki declaration. Informed consent was systematically obtained. All patients were granted ultrahypofractionation as part of a clinical trial (NCT02361515).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 28 November 2019 Accepted: 8 April 2020
Published online: 19 April 2020

References

1. Widmark A, Gunnlaugsson A, Beckman I, Thellenberg-Karison C, Hoyer M, Lagerfeld M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2019;20(4):412–25. https://doi.org/10.1016/S1470-2045(18)30362-5.
2. King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2013;109:217–21.
3. de Crevoisier R, Chauvet B, Baillot I, Lafond C, Mahé M, Delpon G. Radiothérapie guidée par l’image. Cancer/Radiation Therapy. 2016;20:527–35.
4. Latorzeff I, Mazurier J, Boutry C, Dudeout P, Richaud P, de Crevoisier R. Benefit of intensity modulated and image-guided radiotherapy in prostate cancer. Cancer Radiother J Soc Francaise Radiother Oncol. 2010;14:479–87.
5. Pang EP, Knight K, Hussain A, Fan Q, Baird M, Tan SXF, et al. Ultra-hypofractionated radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2013;109:217–21.
6. Picardi C, Rouzaud M, Kountouri M, Lestrade L, Vaille JP, Caparrotti F, et al. Impact of hydrogel spacer injections on interfraction prostate motion during prostate cancer radiotherapy. Acta Oncol Stockholm Sweden. 2016;55:834–40.
7. Juneja P, Kneebone A, Booth JT, Twilley DJ, Kaur R, Colvill E, et al. Prostate motion during radiotherapy of prostate cancer patients with and without application of a hydrogel spacer: a comparative study. Radiat Oncol Lond Engl. 2015;10:215.
8. Hedrick SG, Fagundes M, Robison B, Blakey M, Renegar J, Artz M, et al. A comparison between hydrogel spacer and endorectal balloon: an analysis of interfraction prostate motion during proton therapy. J Appl Clin Med Phys. 2017;18:106–12.
9. Chapet O, Udrescu C, Devonec M, Tanguy R, Sotton M-P, Enachescu C, et al. Prostate hypofractionated radiation therapy: injection of hyaluronic acid to better preserve the rectal wall. Int J Radiat Oncol Biol Phys. 2015;8:72–6.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.